Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share

Author: Benzinga Newsdesk | August 02, 2024 07:07am

Posted In: FLGT